On balance, access to cancer drugs is better in the U.S. More drugs get approved and at a faster pace, with fewer reimbursement restrictions, higher patient cost-sharing notwithstanding.
Better U.S. Patient Access To Cancer Drugs Comes At A Price
On balance, access to cancer drugs is better in the U.S. More drugs get approved and at a faster pace, with fewer reimbursement restrictions, higher patient cost-sharing notwithstanding.